Lantern Pharma Inc (LTRN)

$2.33 +0.11 (4.95%)
Market Cap 22.17M
Revenue (ttm) 0.00
Net Income (ttm) -17.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 275,700
Avg Vol 652,120
Day's Range N/A - N/A
Shares Out 11.26M
Stochastic %K 100%
Beta 1.75
Analysts Strong Sell
Price Target $25.00

Company Profile

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical tria...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 277 1136
Address:
1920 McKinney Avenue, 7th Floor, Dallas, United States
Msjishi
Msjishi Apr. 14 at 9:37 PM
$LTRN
0 · Reply
SevenPhigs27
SevenPhigs27 Apr. 14 at 4:12 PM
$LTRN Not an analyst by trade but I'd be curious to see what reports emerge after these next set of demos. Cash burn last year was approximately $18MM so any projected revenues divided by the 12MM total diluted shares & no warrants would be a future increase in SE even without what's happening in the ongoing clinical pipelines. GLTA
0 · Reply
Bulltrader988
Bulltrader988 Apr. 14 at 2:36 PM
$LTRN 👃👀 https://www.stocktitan.net/news/LTRN/lantern-pharma-launches-with-zeta-ai-the-world-s-first-multi-agentic-6e8y99npo3te.html
0 · Reply
SevenPhigs27
SevenPhigs27 Apr. 14 at 12:48 PM
$LTRN If you do the math it gets interesting. GLTA
0 · Reply
BernardFife
BernardFife Apr. 13 at 9:03 PM
$LTRN Nice to see $LTRN fight its way back.
0 · Reply
emw3000
emw3000 Apr. 13 at 7:41 PM
$LTRN
0 · Reply
AshToFlame
AshToFlame Apr. 9 at 5:05 PM
$VATE $TBH $LTRN $INTC >>6
0 · Reply
Bulletproof99
Bulletproof99 Apr. 9 at 12:25 AM
Let’s swing it people! $LTRN $ARIA $HIMX $BBGI $BBAI Another Green Day all day!
0 · Reply
mankind1
mankind1 Apr. 8 at 8:15 PM
$LTRN https://www.stocktitan.net/sec-filings/LTRN/schedule-13g-lantern-pharma-inc-passive-investment-disclosure-5-4f16ca3e020e.html
0 · Reply
Msjishi
Msjishi Apr. 8 at 8:15 PM
$LTRN
0 · Reply
Latest News on LTRN
Lantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22

Apr 14, 2026, 8:31 AM EDT - 11 hours ago

Lantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22

Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026

Apr 2, 2026, 8:10 AM EDT - 12 days ago

Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 30, 2026, 4:05 PM EDT - 15 days ago

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

Mar 27, 2026, 7:23 PM EDT - 18 days ago

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

Mar 27, 2026, 7:29 AM EDT - 18 days ago

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

Mar 23, 2026, 4:30 PM EDT - 22 days ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026

Feb 10, 2026, 8:45 AM EST - 2 months ago

Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Jan 20, 2026, 8:00 AM EST - 3 months ago

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies

Jan 12, 2026, 9:00 AM EST - 3 months ago

Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies

Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials

Dec 3, 2025, 8:35 AM EST - 4 months ago

Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 13, 2025, 8:30 AM EST - 5 months ago

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

Nov 6, 2025, 8:00 AM EST - 5 months ago

Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

Oct 30, 2025, 8:00 AM EDT - 5 months ago

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.

Oct 28, 2025, 8:49 AM EDT - 6 months ago

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025

Oct 24, 2025, 8:00 AM EDT - 6 months ago

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025

Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

Sep 16, 2025, 8:29 AM EDT - 7 months ago

Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)

Sep 10, 2025, 8:00 AM EDT - 7 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)

Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

Sep 3, 2025, 9:44 AM EDT - 7 months ago

Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

Aug 13, 2025, 4:30 PM EDT - 8 months ago

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Aug 6, 2025, 8:30 AM EDT - 8 months ago

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

Aug 4, 2025, 8:55 AM EDT - 9 months ago

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Jul 31, 2025, 7:30 AM EDT - 9 months ago

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

Jul 28, 2025, 8:00 AM EDT - 9 months ago

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

Jul 23, 2025, 7:56 AM EDT - 9 months ago

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

Jul 21, 2025, 8:20 AM EDT - 9 months ago

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

Jul 15, 2025, 9:40 AM EDT - 9 months ago

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

Jun 16, 2025, 8:30 AM EDT - 10 months ago

Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

May 29, 2025, 8:30 AM EDT - 11 months ago

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

May 15, 2025, 8:45 AM EDT - 11 months ago

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

May 12, 2025, 9:00 AM EDT - 1 year ago

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

May 8, 2025, 8:30 AM EDT - 1 year ago

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

May 5, 2025, 8:55 AM EDT - 1 year ago

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Feb 19, 2025, 8:00 AM EST - 1 year ago

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Jan 27, 2025, 7:55 AM EST - 1 year ago

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Dec 9, 2024, 8:15 AM EST - 1 year ago

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Dec 3, 2024, 8:00 AM EST - 1 year ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Nov 26, 2024, 8:45 AM EST - 1 year ago

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Nov 19, 2024, 8:00 AM EST - 1 year ago

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Nov 7, 2024, 4:05 PM EST - 1 year ago

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Nov 5, 2024, 8:00 AM EST - 1 year ago

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Oct 23, 2024, 8:45 AM EDT - 1 year ago

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Lantern Pharma to Host & Participate in Two Public Webinars During October

Oct 21, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma to Host & Participate in Two Public Webinars During October

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Oct 15, 2024, 9:07 AM EDT - 1 year ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Aug 7, 2024, 9:31 AM EDT - 1 year ago

Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Msjishi
Msjishi Apr. 14 at 9:37 PM
$LTRN
0 · Reply
SevenPhigs27
SevenPhigs27 Apr. 14 at 4:12 PM
$LTRN Not an analyst by trade but I'd be curious to see what reports emerge after these next set of demos. Cash burn last year was approximately $18MM so any projected revenues divided by the 12MM total diluted shares & no warrants would be a future increase in SE even without what's happening in the ongoing clinical pipelines. GLTA
0 · Reply
Bulltrader988
Bulltrader988 Apr. 14 at 2:36 PM
$LTRN 👃👀 https://www.stocktitan.net/news/LTRN/lantern-pharma-launches-with-zeta-ai-the-world-s-first-multi-agentic-6e8y99npo3te.html
0 · Reply
SevenPhigs27
SevenPhigs27 Apr. 14 at 12:48 PM
$LTRN If you do the math it gets interesting. GLTA
0 · Reply
BernardFife
BernardFife Apr. 13 at 9:03 PM
$LTRN Nice to see $LTRN fight its way back.
0 · Reply
emw3000
emw3000 Apr. 13 at 7:41 PM
$LTRN
0 · Reply
AshToFlame
AshToFlame Apr. 9 at 5:05 PM
$VATE $TBH $LTRN $INTC >>6
0 · Reply
Bulletproof99
Bulletproof99 Apr. 9 at 12:25 AM
Let’s swing it people! $LTRN $ARIA $HIMX $BBGI $BBAI Another Green Day all day!
0 · Reply
mankind1
mankind1 Apr. 8 at 8:15 PM
$LTRN https://www.stocktitan.net/sec-filings/LTRN/schedule-13g-lantern-pharma-inc-passive-investment-disclosure-5-4f16ca3e020e.html
0 · Reply
Msjishi
Msjishi Apr. 8 at 8:15 PM
$LTRN
0 · Reply
Bulletproof99
Bulletproof99 Apr. 8 at 7:50 PM
$BBGI Dump your profit here for tomorrow $LTRN 👈 Last call! ☎️
0 · Reply
SevenPhigs27
SevenPhigs27 Apr. 8 at 4:15 PM
$LTRN If the Company had some trial data updates set for release this upcoming week or soon thereafter, it would pose an interesting scenario considering the limited share supply turning over what was approximately less than the 11MM o/s float, very conservatively speaking. No rush. Just food for thought as I believe there are some deep eyes on this one regardless of when. Longeveron recently did a financing deal which I didn't find anything too special at all and only gives them runway to EOY I believe. Don't follow that one closely.
0 · Reply
mankind1
mankind1 Apr. 8 at 4:04 PM
$LTRN This should be over 3. Too much good news.
0 · Reply
Bulletproof99
Bulletproof99 Apr. 8 at 3:59 PM
$LTRN cooking for tomorrow! $BBAI $HIMX $MVST
0 · Reply
GSTX7
GSTX7 Apr. 7 at 8:00 PM
$LTRN
0 · Reply
Bulletproof99
Bulletproof99 Apr. 7 at 7:15 PM
$LTRN swinging the winning!
0 · Reply
Bulletproof99
Bulletproof99 Apr. 7 at 11:29 AM
Round 2!! $MVST $LTRN $BATL
0 · Reply
mankind1
mankind1 Apr. 6 at 3:48 PM
$LTRN come on..
0 · Reply
Bulletproof99
Bulletproof99 Apr. 6 at 1:37 PM
$UMAC $LTRN $COCP All breaking out come come come!!
1 · Reply
Bulltrader988
Bulltrader988 Apr. 3 at 7:20 PM
$LTRN 13G filled today: Thomas A. Satterfield, Jr. 570,000 shares = 5.1 % ownership 👃👀 https://www.sec.gov/Archives/edgar/data/1132317/000110465926039486/xslSCHEDULE_13G_X02/primary_doc.xml
0 · Reply
BernardFife
BernardFife Apr. 3 at 3:57 PM
$LTRN Someone with more knowledge than me may find some importance in this filing today? https://ir.lanternpharma.com/financials/sec-filings/sec-filings-details/default.aspx?FilingId=19319274
0 · Reply
Bulletproof99
Bulletproof99 Apr. 3 at 4:00 AM
Swinging $UMAC $LTRN $COCP Lottery $KIDZ
0 · Reply